Use of cannabinoids in the treatment of epilepsy
US11096905B2 · kind B2 · utility
38Cited by
37References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 11, 2021 |
| Grant date | Aug 24, 2021 |
| Priority date | — |
| Expiry date | Mar 11, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.